CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics


0.01 (-3.51%)

POWR Rating

Component Grades








CNSP Price/Volume Stats

Current price $0.22 52-week high $2.98
Prev. close $0.22 52-week low $0.19
Day low $0.21 Volume 197,800
Day high $0.24 Avg. volume 370,745
50-day MA $0.27 Dividend yield N/A
200-day MA $1.07 Market Cap 2.57M

CNSP Stock Price Chart Interactive Chart >


CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

CNSP Latest News Stream

Event/Time News Detail
Loading, please wait...

CNSP Latest Social Stream

Loading social stream, please wait...

View Full CNSP Social Stream

Latest CNSP News From Around the Web

Below are the latest news stories about CNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNSP as an investment opportunity.

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Independent DSMB recommends continuing clinical trial of Berubicin without modificationEnrollment expected to be complete in early Q1 2024HOUSTON, TX / ACCESSWIRE / December 18, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (CNS or the Company), ...

Yahoo | December 18, 2023

CNS Pharmaceuticals files to sell 3.81M shares of common stock

More on CNS Pharmaceuticals


Seeking Alpha | December 8, 2023

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms of cancer that are more deadly. Glioblastoma (GBM) is a highly aggressive ...

Yahoo | December 6, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM)Topline result from preplanned interim futility analysis ...

Yahoo | November 22, 2023

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

HOUSTON, TX / ACCESSWIRE / November 16, 2023 / Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months. With no approved treatment for recurrent GBM anywhere ...

Yahoo | November 16, 2023

Read More 'CNSP' Stories Here

CNSP Price Returns

1-mo 8.91%
3-mo N/A
6-mo -89.47%
1-year -86.16%
3-year -99.61%
5-year N/A
YTD -82.68%
2023 -47.08%
2022 -88.61%
2021 -60.54%
2020 -54.94%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!